Xintela publishes Phase I/IIa data showing XSTEM improves pain, function in knee osteoarthritis study
Reuters2026/08/11 06:35- Xintela published peer-reviewed Phase I/IIa results for XSTEM in knee osteoarthritis in the journal Cartilage; results were previously presented in September 2025.
- The study showed the treatment was well tolerated, with no serious treatment-related safety issues reported.
- Patients reported reduced knee pain and improved joint function, supporting a potential disease-modifying effect.
- The highest dose showed sustained improvements in cartilage and bone tissue quality for up to two years, with signs of slowing cartilage breakdown.
- Publication increases visibility of the dataset for potential partners, strengthening the investment case for further development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OpenAI enterprise business shows "strong momentum," CFO: 32% month-on-month growth in July
According to media reports, OpenAI CFO Sarah Friar stated that the company's enterprise business has performed "very strongly" recently; OpenAI's overall annualized revenue run rate in July increased by 20% compared to the previous month, with enterprise business up 32% month-on-month, outpacing the growth of personal consumer business.
Elastic CTO Shay Banon reports disposal of Elastic common shares worth $26.79 million
Progressive Planet Solutions Names Kyle Dickson Interim CFO, Adds Dave Barnett to Board